Home/Pipeline/SDC-1801

SDC-1801

Autoimmune Diseases

Phase 1/2Active

Key Facts

Indication

Autoimmune Diseases

Phase

Phase 1/2

Status

Active

Company

Sareum

About Sareum

Sareum Holdings PLC is a public, clinical-stage biotech developing novel kinase inhibitors with a primary focus on dual TYK2/JAK1 inhibition for autoimmune conditions and cancer. Its lead asset, SDC-1801, is advancing through Phase 2-enabling studies, while a second program targets the CHK1 kinase in oncology. Headquartered in Cambridge, UK, the company leverages its expertise in kinase biology to pursue best-in-class therapeutic candidates in high-value markets, though it remains pre-revenue and faces the typical risks of drug development.

View full company profile

Therapeutic Areas

Autoimmune Diseases Oncology

Other Autoimmune Diseases Drugs

Drug	Company	Phase	Status
Humira (Adalimumab) Biosimilar	NeuClone	Early Preclinical	Active
HBM7020	Harbour BioMed	Discovery	Out-Licensed
R2006	Harbour BioMed	Discovery	Active (Global)
R7027	Harbour BioMed	Discovery	Active (Global)
ImmCelz™ Platform	Creative Medical Technology Holdings	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Gavocabtagene autoleucel	astellas	Phase 1/2	Active
TYK-101	TYK Medicines	Phase 1	Active
HCB206	HanchorBio	Preclinical	Active
miR-124 Activator	Formation Bio	Phase 2	Active
Autologous Cell Therapy Collaboration	Lupagen	Preclinical	Active
Autoimmune Diagnostics Leadership Initiative	Vibrant America Clinical Laboratory	Commercial	Active